Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

The clinical trial concerns the use of an innovative \"anti-emetic\" drug (that is, anti-vomiting and nausea) in subjects affected by endometrial cancer. It is addressed to patients who have never received chemotherapy before and are about to start a treatment with platinum and taxanes with or without immunotherapy for endometrial cancer. The primary objective of the study is to learn if the drug is able to avoid the occurrence of vomiting and post- nausea chemotherapy within 120 hours after cycle 1 with carboplatin and paclitaxel with or without immunotherapy. Partecipants will take

Trial Details

NCT ID
NCT06726291
Phase
PHASE4
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • NEPA (300mg netupitant/0.5mg palonosetron)
Locations (sample)
  • Brescia, BS, Italy|45.53558,10.21472
  • Lecco, LC, Italy|45.85589,9.39704
  • Padova, PD, Italy|45.50094,9.23458
  • Aviano, PN, Italy|46.07056,12.59472
  • Torino, TO, Italy|44.88856,11.99138

Key Eligibility Criteria

  • Subject is at least 18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed …
  • Subject has histologically or cytologically proven endometrial cancer
  • Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical pra…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →